ido inhibitor 1

IDO inhibitor 1 是一种有效的吲哚胺-2,3 双加氧酶 (IDO) 抑制剂 (IC50 <100 nM)。具有潜在的免疫调节和抗肿瘤活性。

Epacadostat (INCB 024360) 是一种口服、高效且具有选择性的 IDO1 抑制剂，IC50值为71.8 nM。

PCC0208009 (IDO-IN-2) 是一种有效的 IDO 抑制剂，其在 HeLa 细胞中的 IC50=4.52 nM。它调节 ACC 和杏仁核的突触可塑性，减少神经性疼痛和合并症。

IDO1 and HDAC1 Inhibitor is a dual IDO1 and HDAC1 inhibitor (IC50s: 69.0 nM and 66.5 nM).

Necrostatin-1 (Nec-1) 是一种坏死性凋亡抑制剂和 RIP1 抑制剂，具有特异性。Necrostatin-1 抑制 TNF-α 诱导的坏死性凋亡。Necrostatin-1 也可以抑制 IDO。

Palmatine chloride 是口服具有活力的不可逆 IDO-1抑制剂。它能够减轻结肠损伤，预防肠道菌群失调和调节色氨酸分解代谢，并改善 DSS 诱发的结肠炎。

Palmatine (Burasaine) 是口服具有活力的、不可逆IDO-1抑制剂。它可以减轻结肠损伤，预防肠道菌群失调和调节色氨酸分解代谢，从而改善DSS (Dextran Sulphate Sodium Salt) 诱发的结肠炎。它有用于结肠炎的研究潜力。

Indoximod (NLG-8189) 是一种具有口服具有活力的吲哚胺2,3-双加氧酶(IDO) 途径抑制剂。它在调节 mTOR 中充当 Trp 模拟物。它是一种可用于癌症研究的免疫代谢佐剂。

PF-06840003 (EOS200271) 是口服具有活力的、选择性的IDO-1抑制剂，抑制 hIDO-1， dIDO-1和 mIDO-1 的IC50分别为 0.41 μM， 0.59 μM，和 1.5 μM。

Necrostatin 2 racemate (Necrostatin-2 racemate) 是一种特异性的RIPK1抑制剂，是一种稳定型 Nec-1。

IDO1-IN-1 (2 HzBTZ) 是一种吲哚胺 2,3-双加氧酶 1 (IDO1) 抑制剂。

IDO-IN-13 (GS-4361) 是 indoleamine 2,3-dioxygenase 1 抑制剂，EC50=17 nM。

IDO-IN-4 is an indoleamine 2,3-dioxygenase 1 (IDO-1) inhibitor.

IDO-IN-5 is an indoleamine 2,3-dioxygenase (IDO) inhibitor (IC50: 1-10 μM).

IDO-IN-8 is an indoleamine 2,3-dioxygenase (IDO) inhibitor (IC50: 1-10 μM).

IDO TDO-IN-1 is an orally active dual indoleamine-2,3-dioxygenase (IDO) and tryptophan 2,3-dioxygenase (TDO) inhibitor (IC50s: 9.7 and 47 nM).

LY3381916 是可透过血脑屏障的、选择性的IDO1抑制剂，能够与缺乏血红素的 apo-IDO1 结合，但无法与成熟血红素的 IDO1 结合。

Benzomalvin C is a weak antagonist of the neurokinin-1 (NK1) receptor inhibiting binding of substance P by 46% when used at 100 μg ml in vitro. It is also a weak inhibitor of indolamine 2,3-dioxygenase (IDO) with an IC50 value of 130 μM for recombinant IDO. It was isolated from Penicillium and contains an epoxide group at C-19 and C-20, which is not present in benzomalvins A, B, or E.

Acid secretion-IN-1, a polycyclic compound, is synthesized for its application as an IDO inhibitor in synthetic experiments.

eIF4E-IN-1 (WO2021003194A1, compound Y), is a highly effective inhibitor of eIF4E, a key protein involved in immunosuppression. By targeting immune checkpoint proteins such as PD-1, PD-L1, LAG3, TIM3, and IDO, eIF4E-IN-1 functions to disrupt immune suppression and promote immune release in specific diseases such as cancer and infectious diseases.

(Rac)-Indoximod (1-Methyl-DL-tryptophan) is a potent inhibitor of indoleamine 2,3-dioxygenase (IDO). Combined treatment with IFN-γ and (Rac)-Indoximod significantly suppresses the activity of α-SMA-expressing human cardiac myofibroblasts (hCMs) and promotes apoptosis by up-regulating the genes IRF-1, Fas, and FasL. Moreover, this co-treatment effectively improves cardiac fibrosis[1].

IDO-IN-1 是吲哚胺-2,3-双加氧酶抑制剂，IC50=59 nM。

Palmatine hydroxide 是不可逆的口服活性IDO-1抑制剂，其对HEK 293-hIDO-1 和 rhIDO-1的IC50值分别为3 μM和157 μM。该化合物还能非竞争性抑制(WNV)NS2B-NS3蛋白酶，IC50值为96 μM。Palmatine hydroxide展现了抗癌、抗炎、神经保护、抗细菌和抗病毒的活性。

IDO Tubulin-IN-2 (HT2) 是一种对TDO和微管蛋白 (tubulin)展现出高效抑制作用的化合物。该抑制剂对多种癌细胞系（包括U87、HepG2、A549、HCT-116和LO2）均表现出强抗肿瘤活性，其半抑制浓度（IC50）分别为0.43、0.036、0.041、0.095和1.04 μM，有效提升了抗肿瘤效果。